Canada’s IP Policies Need New Look

06.06.14 | By

The current intellectual property (IP) environment in Canada has caused increased friction with its closest allies, particularly in the area of IP rights protections for biopharmaceutical products. By revoking 19 patents since 2005 through questionable decisions, Canadian courts have set a disturbing precedent that risks future investments in cutting-edge R&D projects in innovative industries, and the high-paying jobs that accompany them.

Celebrating Survivors: A Pioneer in Leukemia Treatment and Hope For A Cure

06.04.14 | By

On June 1, patients around the world participated in a very special celebration, National Cancer Survivors Day. This is a day everyone in remission hopes for, and one those currently in treatment are working so hard to achieve.

In the United States alone, it is estimated there are 14 million people who have faced the challenges of a cancer diagnosis and are winning

PhRMA and Georgetown University Establish New Fellowship in Regulatory Science

06.04.14 | By

The process of translating biomedical discoveries into novel therapies continues to increase in complexity as science and technology rapidly evolve. To ensure timely patient access to safe and effective innovative medical products, it is critical that the science of drug review and evaluation keeps up with rapid advances in drug discovery and development, so that experts across the ecosystem are able to understand, adopt and apply new scientific tools, standards, and approaches in evidence-based decision making processes.

Are Health Insurance Exchange Cost-Sharing Reductions Really Helping Low-Income Patients Access Medicines?

06.03.14 | By

Ensuring that patients have access to the medicines they need is at the heart of what biopharmaceutical research companies do every day. The Affordable Care Act put in place a new way for Americans to access health insurance coverage and even provides assistance in the form of tax credits and cost-sharing reductions for those who need it most.

#ASCO14: Patients Should Be at the Center of the Value Proposition

05.31.14 | By

Yesterday, ASCO held a panel entitled, “Can We Find Common Ground? Stakeholder Perspectives on Value in Cancer.” At the tail end, a woman stepped to the mike to make an observation to the panelists. Describing herself as a patient and an advocate, she declared that she heard little in the presentations about patient-reported outcomes, particularly in reference to ASCO's value initiative that is in the works.

 

Castellani Op-Ed in The Hill: Health insurance model must evolve

05.31.14 | By

In case you missed it, The Hill featured an op-ed by PhRMA President and CEO John J. Castellani, “Health insurance model must evolve,” to coincide with the start of the American Society of Clinical Oncology’ (ASCO) 50th anniversary conference.

Week in Review: The Price of Innovation & Patient Well-Being

05.30.14 | By

The cost of innovative new medicines to treat devastating diseases such as cancer and Hepatitis C has been a hot discussion topic this week. A critical part of this discussion – the value of these treatments – however, has been overlooked. As our President and CEO John Castellani said, focusing solely on the cost of a new treatment and ignoring its subsequent value is “penny wise and pound foolish” because prescription medicines provide patients and the health care system long-term cost savings.

PhRMA Statement on FDA Draft Guidance on Labeling for Products Approved Under the Accelerated Approval Pathway

Washington, D.C. (May 30, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, PhD, issued the following statement on the Food and Drug Administration (FDA) draft guidance on labelling for human prescription drug and biologics approved under the Accelerated Approval pathway:

Achieving the shared goal of bringing safe and effective new medicines to patients

05.30.14 | By

Each patient facing a life-threatening disease lives with the hope that tomorrow will bring a new medicine to extend and improve his or her life.  As a scientist, a new father, and as someone who lost a parent to stage IV lung cancer far too early in life, it is gut-wrenching to admit that modern drug development continues to be a highly challenging and far too often unsuccessful endeavor. 

Transforming Healthcare One Employee at a Time

05.30.14 | By

Businesses know the impact of poor health and see first hand how some communities are affected more than others. Truly improving health takes time, effort and investment from all of us. With one out of two Americans having at least one chronic condition, the costs of chronic disease are staggering and affect every community, every business, and every person.

Pages

Subscribe to RSS - Opinion